Claritas Collaborates with CMAX to Initiate P-I Study of R-107 for Pulmonary Arterial Hypertension
Shots: Alphamab to receive upfront, milestones and royalties on sales of KN035 (ASC22). Ascletis to get exclusive development and commercialization rights for Alphamab’s KN035 (ASC22) in Greater China Alphamab will be responsible to manufacture and commercialize ASC22 (KN035) in Greater China and Ascletis to receive economics (Ex-China) from Alphamab on its regulatory approval in China […]Read More
